Abstract To investigate the value of combined detection of the levels of placenta protein-13 (PP13), placental growth factor (PIGF), and soluble vascular endothelial growth factor receptor-1 (sFlt-1) for predicting and diagnosing preeclampsia early. Methods: Between January 2018 and June 2019, a prospective study was conducted in 800 pregnant women. The general situation and the serum factor changes of these women during the first, second, and third trimester of pregnancy. 68 women with preeclampsia were in group A (women with mild preeclampsia in group A1 and women with severe preeclampsia in group A2), and 732 women withou preeclampsia were in group B. The levels of PP13, PIGF, sFlt-1 of women were compared between group A and group B, and the PP13, PIGF, sFlt-1 levels of women were compared between group A1 and A2. The risk factors of the preeclampsia onset were analyzed, and ROC curve was used to analyze the prediction and diagnostic value of the combination PP13, PIGF and sFlt-1 levels for early preeclampsia. Results: Among the 800 pregnant women, 68 (8.5%) women had developed preeclampsia during pregnancy. There were significant different in PP13, PIGF and sflt-1 levels of women with different degrees of preeclampsia during the first, second, and third trimester of pregnancy (all P<0.05). The sensitivity and the specificity of the combination detection of PP13, PIGF and sflt-1 levels for predicting preeclampsia were 81.01% and 86.32%, and the sensitivity and the specificity of the combination of PP13, PIGF and sflt-1 levels for diagnosing preeclampsia were 80.28% and 88.36%, which were the best. Conclusion: The combination detection of PP13, PIGF and sflt-1 levels can further improve the accuracy of predicting and diagnosing preeclampsia and the severity degree of preeclampsia.
|
|
|
|
|
|
